Tempus AI, Inc. (TEM) Earnings Call Transcript & Summary
February 24, 2025
Earnings Call Speaker Segments
Lizzie Krutoholow
executiveThanks, Jason. Good afternoon, everyone, and welcome to Tempus' conference call for the fourth quarter of 2024. Earlier today, Tempus put out its results for the quarter and for the year that closed on December 31st, 2024. With me on today's call from Tempus are Eric Lefkofsky, our Founder and CEO, and Jim Rogers, our CFO. Before we get started, I want to remind everyone that management might make forward-looking statements on this call, and those statements carry risks and uncertainties that could make actual results come in materially differently. To review those risks, please see our 10-K filed today, February 24th, 2025, along with any reports we file with the SEC going forward. On this call, we'll also talk about non-GAAP financial measures, which aren't prepared in accordance with generally accepted accounting principles. You can find definitions of these non-GAAP financial measures, plus reconciliations to the most directly comparable GAAP financial measures, in our fourth quarter earnings release, which has been furnished to the SEC and is available on our website and at investors.tempus.com. I'd now like to hand the call over to Eric.
Eric Lefkofsky
executiveThanks, and I appreciate all of you being on the call. What I'll do is run through a handful of brief points, and after that we're glad to field questions. For Tempus, Q4 was an outstanding quarter on every front. During the fourth quarter, our revenue growth sped up to 35.8% compared with the prior year. Gross profit growth sped up to 49.7%, so while revenues climbed quickly, gross profit actually climbed at an even faster pace. We finished the year with $940 million in total remaining contract value along with 140% net revenue retention; both of those rose quite substantially. And a contributor to why our gross profit was expanding so fast is that our Data and Services business simply delivered a very strong Q4, capping a very strong year, and that drove part of that growth. That's also why we closed out the year with an increase in total remaining contract value and genuinely record net revenue retention. We also completed the Ambry Genetics acquisition on February 3rd, which is exciting since we've discussed that in the past, but it's now done, so this quarter we'll include two months of Ambry's results in our figures, and we also raised our revenue guidance; previously we'd provided $1.23 billion, but we've lifted that to $1.24 billion for 2025 and expect to be right at Adjusted EBITDA positive while producing roughly $5 million of Adjusted EBITDA. Naturally, we aren't giving a range. We provide fairly specific numbers, though a range is always implied, but our confidence is sufficient that we're raising our guidance for 2025. Lastly, I'd just mention, if you look at the letter Jim and I released, you'll find this in a section, but we did extend our Google agreement by another five years. It's sort of a terrific win for us because it lets us take advantage of truly best-in-class rates, and it extends the note we hold with Google by another five years. And that note, as you remember, decreases as we spend on their platform, so we get more opportunity to pay it down. So altogether, a great quarter. It's exactly where we want to be. You want revenues speeding up in terms of growth. Our gross profits are rising faster. Our costs are aligned. So we're producing the sort of leverage we're looking for. It's genuinely just good to be in a spot where certainly our two core businesses, genomics and data, are truly operating at full power and in a strong stretch. With that said, I'm glad to take questions.
Tejas Savant
executiveHi everyone, good evening, and congratulations on getting the Ambry deal done. Eric, I've got just one thing to ask on that. You mentioned that one advantage of acquiring Ambry and making it part of the company is gaining a lab on the West Coast. So how long might it take before we start to see some of your somatic workflows moved to that site? Then, Jim, regarding seasonality within the Ambry business, what should we assume is baked into the guidance? Clearly, with only 2 months of contribution in 1Q, there's going to be a mathematical step-up; but past that, is there anything else we should keep in mind about seasonality across the year?
Eric Lefkofsky
executiveRight, I'll begin. For anyone who doesn't remember, Ambry provides us with a laboratory on the West Coast. Our facilities are located in Chicago, Raleigh, North Carolina, and Atlanta; with this acquisition of Ambry, we've gained a site in the western part of the country. Eventually, we intend to have our somatic or CGP tests, meaning comprehensive genomic profiling tests, performed at that facility. We plan to move certain inherited risk tests from them into our own facilities; however, we have no plans to do so right away within the coming few quarters; this is a longer-term effort aimed at ensuring we maintain suitable backup capabilities at each of our major laboratories nationwide. It's lucky for us that Tempus currently operates that way already, with Chicago and Raleigh. So a great deal of that redundancy has been established, including with regard to operational processes. Should one laboratory encounter an issue or go offline, we also gain from a degree of reimbursement variety thanks to those two sites, and Ambry's California laboratory will provide us with further redundancy and further advantages, so I'd say within the coming 1 or 2 years, we'll aim to begin relocating a portion of those tests and exchanging expertise.
Jim Rogers
executiveRight, and for the second question about how Ambry's business swings with the seasons — I believe they see the same seasonal pattern we and other labs do. Things generally ease off around the holidays. That said, considering where they stand when it comes to grabbing market share and expanding their rare and undiagnosed work, we'd expect revenues to climb across the year, much like they do in the Tempus business. So seasonality does exist, but we'd simply expect revenues to keep rising each quarter, just like the Tempus business.
Tejas Savant
executiveUnderstood. Now, a brief follow-up regarding the data aspect: during your prepared comments, you noted one data delivery project, as I recall, that moved outside the quarter. Could you quantify what that impact was, and did a customer cause the delay? Also, Jim, related to that point, what precisely is the data contribution you're including in your guidance? Should we view it as a conservative figure that's basically de-risked, or does some sensitivity exist tied to pharma budgets, especially among smaller customers who haven't entered those strategic longer-term contracts with you?
Eric Lefkofsky
executiveRight. I'll begin with the first point. We had a pretty sizable data delivery worth more than $10 million, and we could have pushed to get it out possibly during Q4, but its normal timing falls in the early portion of this year. The reason I brought it up is simply that it wasn't a case of the client having a problem, or us having a problem, or any problem at all. It's just that each quarter, once you reach our scale and operate a data business this big, the scheduling of these data set deliveries can shift by a month in one direction or another. They may move forward into a quarter. They may move back into a quarter. So there are always puts and takes, and that's what I was pointing out. Had that data delivery gone out during Q4, we would have done so. You can add a significant amount of revenue to Q4. So it would have been. That's also why I said that when we discuss $700 million of revenue, it might be $693 million. It might be $706 million. And most of that has nothing to do with how the business is performing or what's going well; it can simply come down to when tests get ordered or when data gets delivered.
Jim Rogers
executiveNow, regarding the latter portion of what you asked, Tejas, about the 2025 guidance and how data factors into it. Obviously, that $940 million figure for total remaining contract value provides solid visibility as we head into 2025. Committed spend tends to be part of the bigger deals, and delivery on those larger subscriptions happens on a quarterly basis. When it comes to the smaller deals, a certain portion of them will always be signed and delivered within the year, though as we enter 2025, most of it is already under contract.
Tejas Savant
executiveGot it. That's helpful. Appreciate the time, guys.
Eric Lefkofsky
executiveRight. So what we've said all along — and this shows up in what Jim and I wrote — is that during 2024, Ambry got a lift from some average selling price challenges and from market swings tied to rivals, since a lot of volume was heading their way. On top of that, they've got a top-tier offering that's been expanding faster than the market regardless, so healthy growth was coming either way, yet a few factors in 2024 gave their growth rate extra speed. Then in 2025, once they've cycled past those boosts, you might see a growth rate that would typically sit somewhere around the low 20s land in the high teens instead. We addressed this a quarter ago and figure that's likely how it goes now. Part of this depends on how the year unfolds, but as we've always stated, we're projecting core Tempus at close to 30%, Ambry in the high teens — be it 17% or 19% or anything like that, roughly in that zone — and my guess is that's what happens absent additional boosts coming their way. Understood. That helps; and as a fast follow-up, you brought up that 20% of revenues land in 1Q. I get that you've got the ADLT share of volume rising as the year goes on plus other reimbursement tailwinds. Could you perhaps take us through how the guide phases by quarter and what the exit rate might look like? Thanks.
Jim Rogers
executiveRight. So for us, Q4 is consistently a really large quarter when it comes to data deliveries, like we've mentioned before. Then once you move into Q1, that period tends to be the smallest when you look at its share of total yearly revenue. What we've put out as guidance lines up with patterns from prior years. On the ADLT status point specifically, in the remarks we gave, we're expecting to finish the quarter with roughly 20% of our xT volume having shifted to ADLT. As we've pointed out before, the national rollout kicked off in January, though it's going to take the rest of the year and stretch into next year before nearly all of that testing is on the ADLT version. So we guided toward 20% of revenues in Q1, and we'd expect a similar sort of phasing to what occurred last year. Understood. Thanks.
Mike Ryskin
executiveOkay, thank you for the opportunity to ask. I’d like to build on what Casey just mentioned regarding Ambry’s contribution. I’m hoping we can go a bit further into how you’re viewing the model over a longer horizon. You discussed its impact on growth and how it expanded during 2024, along with some of the factors that sped things up. As we were just saying, it now appears to be in the high teens for 2025. I believe you also said something about expecting 20% growth over the longer term—I just want to confirm I heard that right. If you could explain how we should incorporate that into our model for 2026 and afterward, and share what you anticipate for the Ambry business over the longer term, that would be helpful; I have a follow-up question as well. Thanks.
Eric Lefkofsky
executiveYeah, my guess is we've communicated to folks what sort of long-term growth rate they ought to associate with Tempus. A 25% rate over the long haul is a genuinely strong figure. Our priority is growth that lasts, rather than squeezing out the biggest possible short-term number. That trade-off shows up constantly in how we operate. When something looks like it can be sustained and hold up over time, that's the route we take, rather than grabbing a pile of growth this quarter that won't stick around. Interestingly, we've already witnessed some of this during the year — and I think Jim touched on it too — you're up against a comparison period, and perhaps in 2023 we had some ASP, some cash collections, that 2024 had to lap. That produces these odd situations where growth rates wobble around somewhat. And even at our current size, we aren't a $100 billion operation where swings like that are irrelevant. Given where we stand, bringing in an additional $20 million or $30 million of revenue and then having to lap it can create some headaches. Still, my expectation over the long term is that Ambry's growth rate and ours — meaning within the genomics business — will likely end up fairly comparable. I believe these can sustain a 25% pace for a good while. The data business and the apps business, I'd say, are capable of expanding somewhat faster. So our data and AI applications, which clearly can expand more rapidly, or at least more rapidly, ought to lift core Tempus. As for core genomics, I'd point to comprehensive genomic profiling and therapy selection, minimal residual disease, and inherited risk profiling — each remains a business with enormous growth potential. To me, it's clear that lots and lots of people, maybe even the majority, are going to get profiled for risk down the road; and given that Ambry leads in that area, the arithmetic speaks for itself. If lots and lots of people, or most people, get profiled, you're talking figures in the hundreds of billions — sorry, I mean hundreds of millions. Right now they only run a small share of those tests, so I see plenty of runway, and my expectation is that their growth rates will, with time, come to resemble ours.
Mike Ryskin
executiveAll right, fine. Now, as a bit of a follow-up, I'd like to address the data aspect. First, in some of your prepared comments, you mentioned total contract value. My understanding is that you closed out the year at 940. Throughout the year, it's basically hovered around that level — in the low 900s, such as 920, 930, 940. That's why we've consistently regarded it as a forward-looking signal for growth. What's the right way to view it from here? I mean, your prepared remarks included statements that you actually anticipate a decrease down the road, since it's such a big figure. But still, why shouldn't it serve as a predictor of future revenue growth? Wouldn't you want to see that figure climb?
Jim Rogers
executiveAlright, I'll begin on that point. Feel free to jump in. What I'd say is that the figure did increase as the year went on, and on top of that, the revenue generated from it reached an all-time high, so when you're seeing the sort of top-line expansion we had, any uptick in that metric would leave you quite pleased. How we think about total remaining contract value is that it sits at a solid enough point to offer a degree of insight into revenue over the coming years. Given how much revenue we book annually, the current levels do deliver that kind of visibility. As we've mentioned before, landing bigger deals can cause those figures to swing around a bit, and you aren't signing massive contracts each quarter. We called out a few of the bigger ones inked during the quarter involving BI and Illumina, and once more, we believe it's positioned at a very healthy point for us to hit the goals we're aiming for.
Eric Lefkofsky
executiveYeah, and here's the thing — it comes in fits and starts, okay? The reality that it's increasing, plus the reality that our net revenue retention is so high, tells you the core business is genuinely, genuinely robust, alright? Put simply, if you're sitting on roughly $1 billion of total contract value and you've handed over $250 million within a year, then for that figure to rise, you basically had to book more than that amount. So that's fantastic. That said, sure, ideally you'd want it expanding at your growth rate. So picture it this way: our growth rate is such that you essentially have to book everything you delivered plus, say, whatever, 30% on top, in which case perhaps you'd expect growth of $75 million, yet it rose by just $30 million, right? Even so, you could still say, "Well, I wish it had gone up by $30 million or $40 million more." But you've got close to a $1 billion-dollar cushion sitting in your data business. So it will be lumpy. Some years we might close a $200 million deal from Illumina, and it'll leap right back up; it won't expand perfectly each quarter; it won't expand perfectly each year; so we look at it and say, "The reality that we're finishing the year with more left in the tank than we had at the start, and we just pulled almost $250 million out of the tank, tells you it's incredibly healthy." Over the long haul, though, you're going to want it to keep pace with your growth rate.
Mike Ryskin
executiveAll right. Thanks. I'll get back in the queue.
Ryan MacDonald
analystHi there, I'm covering for Ryan today. I appreciate you letting me ask some questions. It's encouraging to finally hear the official word that you'll be participating as an in-network provider across a number of Blue Cross Blue Shield plans. I'd like to dig into that a little. How much volume growth do you expect this in-network shift to generate? And perhaps even more significant, could you walk us through again what the reimbursement implications are?
Jim Rogers
executiveSure. Regarding those announcements we put out about entering network agreements with certain parties — just to reiterate, the bulk of our business with commercial payers has traditionally been out-of-network. Roughly 50% of our volume comes from Medicare and Medicare Advantage, which means commercial payers account for slightly under half. Basically, whenever we secure a contract with a commercial insurer, that's a clear boost to what we get paid. Our commercial business isn't heavily concentrated in any single payer, so signing an in-network deal with one of them doesn't really shift our overall reimbursement picture in a major way. That said, steadily reducing that commercial portion—roughly 45%—matters over the long haul as we work toward raising ASPs. Looking ahead to 2025, our strongest average selling price benefits come from shifting test volume to the ADLT form of the assay, which mostly affects Medicare and Medicare Advantage testing, though certain commercial testing is affected too. Then there's xF, our liquid biopsy product, which went through Medicare's gap fill process during the past year, producing roughly a $300 increase in Medicare reimbursement. That's yet another favorable factor for 2025, touching around half of the volume we handle. The commercial-side gains are smaller ones and touch a lower share.
Ryan MacDonald
analystUnderstood. That helps, Jim. Now, regarding the regulatory landscape, quite a few shifts have occurred at the FDA, or at least been proposed — a number of them might work in favor of AI businesses — yet there have also been substantial staff reductions that might slow down decisions or the approval of trials. So given what we've observed today and your vantage point, do you view the situation at the FDA, or across the wider federal government, as more of a headwind or a tailwind for Tempus?
Eric Lefkofsky
executiveFor our part, I'd say it's largely a headwind. What I mean is, we're a diagnostics company powered by AI, centered on technology, so — my apologies, it's a tailwind, which is to say an advantage, so from our perspective, we believe we come out ahead as a tech firm, as an organization centered on AI. Changes of this sort are typically attempts to determine how to achieve greater efficiency, more technology, and we believe we stand to gain from that mindset. There might be modest delays tied to staffing as individuals are dismissed at the FDA, but we don't anticipate those being significant, and we don't depend on any FDA rulings being issued that would alter our business, so all things considered, we see it as a tailwind.
Ryan MacDonald
analystUnderstood. Thank you, everyone.
Dan Brennan
analystThanks a lot for taking the questions. I realize there might be one or two items regarding the data side, but my focus was really on what the guidance implies. So when we consider core Tempus expanding at 30%, we probably have that figure reflected in our model, yet we also have data increasing somewhere in the mid-30s%+ while genomics organic is rising in the mid-20s%. Is that roughly the correct range? If that's not the case, could you assist us in working out what appropriate growth rates for those two segments would be?
Jim Rogers
executiveYes. I'd say that's mostly consistent. On the genomics front, clearly, there are some ASP tailwinds at play, so we'd expect revenues to grow faster than volume growth. And data, just like it has this year, is expanding a bit more rapidly than the genomics business. So I believe you're on the right track there.
Dan Brennan
analystUnderstood. Then regarding the margin outlook, that $5 million EBITDA margin, which is solid, could you help unpack it a bit between the core Ambry piece and the core Tempus piece? Also, are any synergies baked in to reach that figure? And what might drive an outperformance of that figure in 2025?
Eric Lefkofsky
executiveYes. So we've taken it into account, and as we've said before, we've treated reaching Adjusted EBITDA and cash flow positive as an objective. That's where our attention has been. When we plan the investments for the coming year, those plans rest on the premise that revenue is expanding at a certain rate and gross profit is expanding at a certain rate. We can put a certain amount into technology, R&D, personnel, all those things; and we aim to drive enough bottom-line improvement to turn positive. We're lucky that we're on the verge of that turn, which is great; and our 2025 guidance suggests we're plainly there. Still, our near-term attention isn't on reaping profits or squeezing out maximum profits. If we exceed EBITDA, you'll probably see us plow more into growth soon. For 2025 specifically, that will be the narrative. We won't try to obliterate that figure simply because we can. If we are obliterating it, we'll put investments, at least to a significant degree, back into the business and back into growth.
Jim Rogers
executiveNow, Dan, regarding what you asked about synergies being included in the guidance — there aren't any major ones factored in there. Our expectation is that we'll operate Ambry essentially as a completely separate entity, at minimum through 2025; therefore, it won't be until we're well into 2026 that we'd actually start seeing anything meaningful.
Dan Brennan
analystGreat. Thank you.
Subbu Nambi
analystHey, everyone. Thanks for taking my questions. Eric and Jim, regarding your 2025 guidance, what is included, if anything, for this year with respect to expectations for improvements in payer coverage for core Tempus tests as a result of the Ambry acquisition and Ambry payer relationships and contracts? That's one, and I have a follow-up.
Jim Rogers
executiveRight. The intersection of those two operations is pretty limited. So when we shift the reimbursement across to Ambry, the effect ends up being quite minor. Figure it's under $10 million. So there isn't a great deal of common ground in the business as it stands today, though we will pick up a modest gain once that reimbursement gets moved over.
Subbu Nambi
analystUnderstood. So more recently, you made public a business deal with ArteraAI to make their prostate prognostic test available on a commercial basis. Could you walk us through how an arrangement to provide a test such as this one comes together? After that, when there are rival options, how do you settle on a single test or a single provider rather than another? And in making that call, what do you place at the top of the list?
Eric Lefkofsky
executiveWell, one point we also emphasized this quarter is that we now have roughly 3,000 U.S. hospitals, or U.S. institutions, linked up. So a meaningful share of the country is connected to Tempus at this stage. That connectivity gives us more than the ability to sequence many patients efficiently, guide them toward the appropriate treatment, and generate lots of data that supports downstream research and development — it also lets us feed these AI-enabled insights back into the American healthcare system at scale, whether those insights help pair patients with a clinical trial, address a care gap, or put an algorithm to work that could be diagnostically useful for a patient so they stay on the correct path. So that connectivity truly sits at the core of the proprietary value Tempus is creating. At scale, which is where we are now, we can put our own algorithms out into the market, or we can put out third-party algorithms. So my expectation is that, over time, you'll see us increasingly add third-party algorithms to our platform, precisely because of that connectivity. So if someone builds a genuinely strong test that's predictive or prognostic or can benefit someone in some way — particularly if it's being reimbursed and has analytical and clinical validation supporting it — we might add it to our platform. We've got a team that evaluates these things and makes those calls; it's usually patient-led and physician-led. What's best for patients? What do our doctors want? But as I've said, looking back historically, it wouldn't surprise me if, over time, we end up with dozens or hundreds of algorithms operating on our platform, or thousands at scale, since we can distribute them in ways other players can't.
Subbu Nambi
analystThank you for that, Eric. I'll get back in the queue.
Doug Schenkel
analystAfternoon, and thanks for fielding my questions. There are two subjects I'd like to address. To begin, regarding MRD, can you tell us when you anticipate data readouts for tumor-naive as well as tumor-informed? That means both products. And on that note, I'd simply like to verify that no revenue guidance is tied to either of them, in light of where reimbursement stands today and the requirement for additional data. That covers the first subject. The second concerns capital deployment. Clearly, you made moves late last year with Ambry. When you consider priorities going forward, how much appetite exists for further M&A, given your balance sheet position and what the market looks like right now? Thanks.
Eric Lefkofsky
executiveSure; let me begin, Jim; regarding MRD, as you know, we've brought a tumor-naive assay to market. Our start was in CRC, and studies tied to that assay have already been released. Additional ones will come with time, though nothing major would radically alter our trajectory. An assay is now in market. Reimbursement has been submitted for. Assuming MolDX doesn't require anything else for reimbursement, we're positioned well to see that assay reimbursed at some point in late 2025; and our following step will be expanding that assay into additional disease areas, into additional subtypes, which we'll pursue over time. Samples are being collected at present, and we'll launch that assay commercially. We keep refining the assay so it becomes more sensitive and the lower limit of detection comes down. That effort continues, and we'll aim to extend it into other disease areas with time. No pivotal study of any kind is required from us. All of that is behind us, and things are already in motion. My sense is the same holds for Personalis. Their assays are in market in non-small cell lung and breast and I/O. They've submitted a substantial amount already. I believe they're in the midst of submitting across the board for reimbursement; they too have, I believe, stated that they anticipate reimbursement appearing at some point later this year, though their filings are what you'd need to read for the latest. On guidance, our long-standing practice is to focus only on what's visible to us. Until we know that assay is getting reimbursed, nothing substantive from it will be included by us. Since, again, we're in a situation where it might be later this year, it might be early next year, it might be Q3, it might be Q4. There's simply no way to know. As soon as reimbursement arrives, we'll begin scaling these assays up far more aggressively, because getting paid is clearly a solid precondition for scaling them up. So that's that. Regarding capital, we likewise stated last quarter that our genomics footprint leaves us feeling fairly good. Our sense is that we've assembled a truly outstanding set of capabilities, genuinely top-tier, at a scope that nobody else matches; because of that, we aren't aiming to make any major moves in that area. What we're always examining are the more modest opportunities tied to data and to AI within our business. So if some small, intriguing target comes along, an acquisition is possible, yet no large deal is currently in view.
Andrew Brackmann
analystHey, everyone. Afternoon. Appreciate you taking my question. Turning to reimbursement — clearly you scored a major victory when the ECG algo secured coverage earlier in the year. On a broader level, does that shift the way you look at whether payers are willing to widen reimbursement for AI-based diagnostics? Or how ought we to regard that as a possible catalyst across the next year or so? Thanks.
Jim Rogers
executiveYes. From where we sit, this has us genuinely thrilled, since it signals that payers are open to covering these kinds of tests when they're clinically validated and deliver clinical utility. That isn't to say we'll arrive at the close of Q1 with hundreds of our algorithms covered. A lengthy path still lies ahead when it comes to obtaining reimbursement for the many different algorithmic diagnostics in our portfolio. The reason we called this out is that, as we've mentioned before, while the road is long, there are certain nearer-term milestones — this being one — showing that reimbursement for these kinds of things can happen, and that's why it has us so excited.
Andrew Brackmann
analystGreat. Thanks for that. And then maybe on the commercial front, just post-Ambry close now, how should we sort of be thinking about any adds or changes to the way that the reps are going to be deployed and incentivized moving forward? Thanks, guys.
Jim Rogers
executiveYeah. So no significant changes. Yeah. The Ambry reps typically sell into genetic counselors. Our reps are selling into kind of oncologists. And so there's not a ton of overlap. And so we don't anticipate there being any significant changes.
Andrew Brackmann
analystThanks, guys.
Mark Schappel
analystGreat. Thank you for taking my question. Eric, the company recently announced the launch of olivia AI, the app for personal health, the personal health concierge app. I was wondering if you could just discuss the significance of the app and how you plan to monetize it.
Eric Lefkofsky
executiveMonetization for the app will come through a monthly subscription, much like ChatGPT. As far as I know, the price is $12 a month right now. It's beginning at a modest scale. The app has only just been launched to a wider group of users; we have to collect feedback from those users; there are changes to make and improvements to pursue. How these products scale isn't something you truly understand until people start engaging; even so, we're extremely enthusiastic about the possibility of delivering our core technology platform, which lets us interpret all of this multimodal data and turn diagnostics intelligent. Taking that to patients at scale is something we're thrilled about; in our view, it's pretty amazing that they can move all their healthcare data around on their phone, keep it in a secure locker, converse with that data, and draw every sort of insight from it through our AI engine. Small, early, yet it could be transformative.
Mark Schappel
analystOkay, thank you. And to follow up on that, would you mind taking us through what you'd consider your two or three main investment priorities for the business over the next year?
Eric Lefkofsky
executiveWhat we need to do is keep our attention on the things that have been delivering results, and ensure we're really keeping our heads down when it comes to growing both our genomics business and our data business, while rolling out our connected network so that our applications business can expand.
Mark Schappel
analystHey everyone, appreciate you squeezing me in.
Dan Arias
analystJim, regarding the data side of things — those $300 million in renewals you mentioned for Astra and GSK — could you remind us when that renewal is scheduled to come up? And has there been any shift in how confident you are that it goes through under the terms in place for the initial agreement?
Jim Rogers
executiveRight, just to remind everyone, roughly $300 million in opt-ins that we flagged within the total remaining contract value basically relate to the final 18 months or so of the AstraZeneca and GSK agreements. There aren't any updates there. We remain several years out from reaching those renewal points, and our confidence regarding their renewal hasn't shifted at all.
Dan Arias
analystAll right, but does that hold?
Eric Lefkofsky
executiveThose renewals fall somewhere between 27 and 29. So we remain years out.
Dan Arias
analystRight, so moving on to Ambry, Jim — clearly the way hereditary is priced hasn't stayed put. Can you give us some sense of what average selling price you're assuming? Perhaps not the precise figure itself, but rather the sort of year-over-year movement you've got built in. And then let me ask one more thing here. Eric, those accelerants you flagged as significant for Ambry — is that purely about cash collection? Is that the piece you mean? Or did you spot other things there that struck you as one-off?
Jim Rogers
executiveRight, regarding what sped things up on the reimbursement front, it was cash collections — basically their collection rates going higher. Then when it comes to ASPs, we haven't put out specific ASP figures for Ambry. Those are ups and downs, same as they are anywhere else. So they'll sign new in-network agreements, and that might shift things one direction, while raising cash collections in the other. So it's give and take, though nothing major in the way of year-over-year movement on the ASP side for Ambry.
Dan Arias
analystAll right. Thanks.
David Westenberg
analystHello, and I appreciate you fielding this. So perhaps I'll address the seasonal patterns of the company in a broader sense. From what I recall, you mentioned that 20% of revenue is what's anticipated for Q1. I realize your expectation is somewhat lower, with just two months of Ambry's contribution, if I'm not mistaken. Could you remind everyone what the typical seasonal rhythm looks like across the year?
Jim Rogers
executiveSure. I'd say the seasonality varies depending on which product line you're looking at, correct? For genomics, our patterns mirror what you'd observe at other labs. Clearly, order volumes drop near the holidays at the close of the year. That makes January a sluggish beginning, much like periods when folks are usually away on vacation. Things slow down somewhat. So on the genomic side, we're just like any other lab. When it comes to data, our weighting generally leans toward the latter half of the year. Many of our discussions and deliveries tend to line up with pharma budgeting cycles, and those generally track the calendar year. So looking back over history, we don't expect any shift in the patterns observed during 2024 and before that. Once more, we'd expect the phasing across 2025 to resemble how things played out in 2024.
David Westenberg
analystThat's quite useful. I liked hearing that a bit of that small reporting delay carries over into January. So moving to the $940 million in contract revenue, I appreciate the context you provided earlier when answering Mike's question regarding how uneven that can be. What's the right way to view the long-term relationship between those two things? Over a longer horizon, ought they to expand at roughly the same pace? Naturally, Data and Services will be uneven; whereas pharma revenue might be recognized more on a straight-line sort of basis. I'm not sure. I'm genuinely asking. And in the past, it represented a smaller share of what many other companies do, yet they've more or less stated that revenue is anticipated in—this revenue, the value is anticipated within the coming 2 years or some kind of recognition window. Does such a recognition window exist for it? Thank you very much.
Eric Lefkofsky
executiveYeah. So data accounts for the majority of our total remaining contract value. And like we just discussed regarding AstraZeneca and GSK, such parties are able to commit to multi-year agreements, five-year agreements, four-year agreements, six-year agreements, whichever it may be; thus, these are multi-year agreements. And when a large agreement is signed, what occurred? If you were—we have certain investors who've held Tempus for quite a while, so they were able to observe the total remaining contract value, which at one point might have been a few hundred million dollars. Then we signed a number of these large agreements, and it surged to $700 million or $800 million or $900 million. So there are years when the total remaining contract value increased by two or 300%. So yes, over the long run, if you consider a 10-year horizon, your total remaining contract value ought to ultimately equal the data you deliver, and it ought to expand at a comparable growth rate. Yet if the bookings, if your bookings figure rises by 200%, it won't magically rise by 30% over the following three years. Put differently, it can be uneven. In certain years it can rise by 200%. In certain years it can rise by 0%. But taken together, it will essentially have to align with your data deliveries; so we had a few very large agreements that were signed. Excellent for us. And so we believe we're in a solid position. The reality that we're still increasing that figure, even following stretches of truly fast bookings growth, once again signals that our data business is performing at full capacity; and regarding the horizon, again, if you consider the magnitude of our total remaining contract value and the magnitude of our data business, I don't know. Roughly speaking, our data business was around $250 million, and there's $940 million; so it spans multiple years.
David Westenberg
analystThat's quite useful. Thanks.
Eric Lefkofsky
executiveIs there anything you'd like to say in closing? If not, I'll gladly take the opportunity to express appreciation to all of you for being on this call, and we'll be with you again in the next quarter.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Tempus AI, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Tempus AI, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Tempus AI, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.